Spironolactone and intermenstrual bleeding in polycystic ovary syndrome with normal BMI

@article{Sabbadin2016SpironolactoneAI,
  title={Spironolactone and intermenstrual bleeding in polycystic ovary syndrome with normal BMI},
  author={Chiara Sabbadin and A. Andrisani and Monica Zermiani and Gabriella Dona' and Luciana Bordin and Eugenio Ragazzi and Marco Boscaro and Guido Ambrosini and Decio Armanini},
  journal={Journal of Endocrinological Investigation},
  year={2016},
  volume={39},
  pages={1015-1021}
}
PurposeSpironolactone (SP) is an effective treatment for polycystic ovary syndrome (PCOS), but it is often associated with menstrual abnormalities whose mechanism is still under investigation. [...] Key Method According to the presence (15 cases) or absence (15 cases) of menstrual bleeding at the 14th day during SP, the patients were divided into two groups, which were then compared using a two-tailed Student’s t test.Expand
Spironolactone in the treatment of polycystic ovary syndrome
TLDR
SP is the only antiandrogen approved for hirsutism in the United States and has been in use for this reason for more than three decades with close to 300 entries in Pub Med. Expand
Persistent amenorrhea and decreased DHEAS to cortisol ratio after recovery from anorexia nervosa
  • A. Andrisani, C. Sabbadin, +5 authors D. Armanini
  • Medicine
  • Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology
  • 2017
TLDR
Long-lasting amenorrhea after recovery from AN is linked with a persistent hypothalamic dysfunction, although other concomitant causes like PCOS and insulin resistance should be considered. Expand
Coadministration of metformin or spironolactone enhances efficacy of rosiglitazone in management of PCOS
  • M. Ganie, Aafia Rashid, +8 authors S. Masoodi
  • Medicine
  • Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology
  • 2019
TLDR
Treatment of women with PCOS using rosiglitazone alone and in combination with spironolactone or metformin is safe and efficacious with limited adverse events however randomized trials with longer duration of follow up are warranted. Expand
Uterine fibroids and risk of hypertension: Implication of inflammation and a possible role of the renin‐angiotensin‐aldosterone system
TLDR
A certain role of progesterone and PR in UF pathogenesis but not in hypertension, progestersone being a mineralocorticoid receptor (MR) antagonist and PRα and PRβ, compared to the surrounding myometrium, are suggested. Expand
Aldosterone in Gynecology and Its Involvement on the Risk of Hypertension in Pregnancy
TLDR
The aim of this mini-review is to report the possible involvement of aldosterone in all these gynecological conditions, suggesting different pathogenetic mechanisms and new target treatments of MR blockers for these diseases. Expand
Licorice: From Pseudohyperaldosteronism to Therapeutic Uses
TLDR
Some interesting therapeutic uses of licorice are linked to its anti-androgen and estrogen-like activity, especially in the treatment of polycystic ovary syndrome (PCOS) in conjunction with spironolactone therapy. Expand

References

SHOWING 1-10 OF 24 REFERENCES
Treatment of polycystic ovary syndrome with spironolactone plus licorice.
TLDR
In patients with PCOS the mineralocorticoid properties of licorice can reduce the prevalence of side effects related to the diuretic activity of spironolactone. Expand
SPIRONOLACTONE, BUT NOT FLUTAMIDE, ADMINISTRATION PREVENTS BONE LOSS IN HYPERANDROGENIC WOMEN TREATED WITH GONADOTROPIN-RELEASING HORMONE AGONIST
TLDR
After a 6-month course of therapy, bone mineral density is reduced in PCOS women given either GnR Ha alone or GnRHa plus flutamide, but not in those receiving GnR Haas plus spironolactone, and this drug could represent a useful tool to prevent skeletal loss in women given GnRHA as well as in other hypoestrogenic conditions, in particular when estrogens are not recommended. Expand
Polycystic ovary syndrome: Implications of measurement of plasma aldosterone, renin activity and progesterone
TLDR
The increase of plasma aldosterone, ARR and blood pressure inPCOS compared with controls is consistent with an increased mineralocorticoid effector mechanism in PCOS; prolonged therapy with spironolactone could counteract both the hyperandrogenism and reduce future cardiovascular risk. Expand
Side-effects of spironolactone therapy in the hirsute woman.
TLDR
Because of the incidence of metrorrhagia at higher dosages, it is recommended that spironolactone be administered cyclically at a starting dosage of 50 mg twice daily on days 4-21 of the menstrual cycle. Expand
Antiandrogenic properties of spironolactone. Clinical trial in the management of female hirsutism
TLDR
Spironolactone administration appears promising in the therapy of female hirsutism, and acne and seborrhoea improved concomitantly. Expand
Epidemiology, diagnosis, and management of polycystic ovary syndrome
TLDR
Proper diagnosis and management of PCOS is essential to address patient concerns but also to prevent future metabolic, endocrine, psychiatric, and cardiovascular complications. Expand
Serum aldosterone concentration and cardiovascular risk in women with polycystic ovarian syndrome.
TLDR
PCOS women show an insulin resistance related increase in serum aldosterone levels, which is linearly related to insulin and homeostasis model assessment in PCOS. Expand
A novel use of spironolactone: treatment of hirsutism.
TLDR
The data suggest that the antiandrogenic properties of spironolactone render it a suitable agent in the treatment of hirsutism. Expand
Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS).
Since the 1990 NIH-sponsored conference on polycystic ovary syndrome (PCOS), it has become appreciated that the syndrome encompasses a broader spectrum of signs and symptoms of ovarian dysfunctionExpand
Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome.
  • Medicine
  • Fertility and sterility
  • 2004
TLDR
PCOS remains a syndrome of ovarian dysfunction along with the cardinal features hyperandrogenism and polycystic ovary (PCO) morphology, and no single diagnostic criterion is sufficient for clinical diagnosis. Expand
...
1
2
3
...